Literature DB >> 19400905

Pathogenesis of chronic urticaria.

A P Kaplan1, M Greaves.   

Abstract

Chronic urticaria is defined as the presence of urticaria (hives) for at least 6 weeks with the assumption that it occurs daily or close to it. If we eliminate physical urticarias and urticarial vasculitis from consideration, the remainder can be divided into autoimmune chronic urticaria (45%) and idiopathic chronic urticaria (55%). The autoimmune subgroup is associated with the IgG anti-IgE receptor alpha subunit in 35-40% of patients and IgG anti-IgE in an additional 5-10%. These autoantibodies have been shown to activate blood basophils and cutaneous mast cells in vitro with augmentation of basophil activation by complement and release of C5a, in particular. Binding methods (immunoblot and ELISA) yield positives in many autoimmune diseases as well as occasional normal subjects or patients with other forms of urticaria but most such sera are non-functional. Activation of basophils or mast cells causing histamine release is quite specific for chronic urticaria and defines the autoimmune subgroup. Although pathogenicity is not formally proven, the antibodies cause wealing upon intradermal injection, and removal of the autoantibody leads to remission. A cellular infiltrate is seen to be characterized by mast cell degranulation and infiltration of CD4+ T lymphocytes, monocytes, neutrophils, eosinophils, and basophils. The intensity of the infiltrate and clinical severity of the disease (including accompanying angio-oedema) is more severe in the autoimmune subpopulation. This latter group also has a higher evidence of human leucocyte antigen DR alleles associated with autoimmunity and a 25% incidence of antithyroid antibodies with diagnosed hypothyroidism in some. Hypo-responsiveness of patients' basophils to anti-IgE and hyperresponsiveness to serum defines another subpopulation (at least 50%) that overlaps the idiopathic and autoimmune subgroups. Hypo-responsiveness to anti-IgE has been shown to be associated with elevated levels of cytoplasmic phosphatases that inhibit degranulation. Reversal of the abnormality is seen with disease remission. Further work will be needed to distinguish whether this is a cause or a consequence of persistent urticaria and to further assess the relationship (or lack thereof) of altered responsiveness (decreased or increased) with the presence or absence of activating autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19400905     DOI: 10.1111/j.1365-2222.2009.03256.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  58 in total

Review 1.  Developments in the field of allergy in 2009 through the eyes of Clinical and Experimental Allergy.

Authors:  H W Chu; C M Lloyd; W Karmaus; P Maestrelli; P Mason; G Salcedo; J Thaikoottathil; A J Wardlaw
Journal:  Clin Exp Allergy       Date:  2010-11       Impact factor: 5.018

2.  Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria.

Authors:  M H Azor; J C dos Santos; E A Futata; C A de Brito; C W Maruta; E A Rivitti; A J da Silva Duarte; M N Sato
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 3.  Biologic agents in the treatment of urticaria.

Authors:  Allen P Kaplan
Journal:  Curr Allergy Asthma Rep       Date:  2012-08       Impact factor: 4.806

Review 4.  Thyroid diseases and skin autoimmunity.

Authors:  Enke Baldini; Teresa Odorisio; Chiara Tuccilli; Severino Persechino; Salvatore Sorrenti; Antonio Catania; Daniele Pironi; Giovanni Carbotta; Laura Giacomelli; Stefano Arcieri; Massimo Vergine; Massimo Monti; Salvatore Ulisse
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

Review 5.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

6.  Up-regulation of chemokine C-C ligand 2 (CCL2) and C-X-C chemokine 8 (CXCL8) expression by monocytes in chronic idiopathic urticaria.

Authors:  J C Santos; C A de Brito; E A Futata; M H Azor; N M Orii; C W Maruta; E A Rivitti; A J S Duarte; M N Sato
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

7.  Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria.

Authors:  Vippan Goyal; Anu Gupta; Onam Gupta; Dhruvendra Lal; Manharan Gill
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 8.  Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases.

Authors:  Hariharan Subramanian; Kshitij Gupta; Hydar Ali
Journal:  J Allergy Clin Immunol       Date:  2016-07-20       Impact factor: 10.793

9.  Angioedema associated with Crohn's disease: response to biologics.

Authors:  Flavio Habal; Vivian Huang
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

10.  Chronic autoimmune urticaria: where we stand?

Authors:  C L Goh; K T Tan
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.